Skip to content
Screener

Alumis Inc. ALMS Business Segments — Research And Development Personnel Related Costs

Similar metrics at other companies

Ocular Therapeutix logo
OCULSingle Reportable — Research And Development Unallocated Expenses Personnel Costs
$12.98M+44.5%
ArriVent BioPharma, Inc. logo
AVBPSingle Reportable — Research And Development Expense Personnel Related And Other Internal Costs
$10.23M+70.3%
Aclaris Therapeutics logo
ACRSSingle Reportable — Research And Development Expense Personnel Charges
$3.04M+1.7%
Dianthus Therapeutics logo
DNTHPersonnel And Related Costs — Research And Development Expense
$8.64M+47.7%
Tyra Biosciences, Inc. logo
TYRAPersonnel Costs — Research And Development Expense
$11.79M+46.9%
Napco Security Technologies logo
NSSCSingle Reportable — Research And Development Expense
$400K+22.0%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+693%
Enterprise value$3.52B+955%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept alms:ResearchAndDevelopmentPersonnelRelatedCosts.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Professional consulting services6,8046,403
Other research and development costs2,3702,296
Internal costs
Personnel-related costs26,06517,659
Facilities and overhead costs5,3735,192
Total research and development expense81,54096,622
General and administrative expenses18,61022,295
Total operating expenses100,150118,917

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s business segments — research and development personnel related costs?
Alumis Inc. (ALMS) reported business segments — research and development personnel related costs of $26.07M in Q1 2026.
How has Alumis Inc.'s business segments — research and development personnel related costs changed year-over-year?
Alumis Inc.'s business segments — research and development personnel related costs increased by 47.6% year-over-year, from $17.66M to $26.07M.
What is the long-term trend for Alumis Inc.'s business segments — research and development personnel related costs?
Over 2 years (2023 to 2025), Alumis Inc.'s business segments — research and development personnel related costs has grown at a 70.0% compound annual growth rate (CAGR), from $32.07M to $92.7M.
What does business segments — research and development personnel related costs mean?
Reflects the total compensation, benefits, and stock-based compensation expenses for employees dedicated to research and development activities. It serves as a proxy for the company's investment in internal human capital and scientific talent.

Ask your AI about Alumis Inc.'s business segments — research and development personnel related costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude